Scalper1 News
Biotech rivals Kite Pharma (KITE) and Juno Therapeutics (JUNO) were up Tuesday after FBR issued a bullish response to their presentations at the American Society of Hematology (ASH) conference. Analyst Ed White lifted his price target on Kite stock to 72 from 65, though he retained his rating of market perform. He made the change Monday afternoon after Kite released an update on its phase-one trial of its treatment KTE-C19 for diffuse large B-cell Scalper1 News
Scalper1 News